Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Genera Biosystems Ltd (GBI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013542
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pathogens; and PapType is a molecular diagnostic test for the detection and genotyping of high risk and low risk types of human papillomavirus that cause cervical cancer or genital warts. GBL uses AmpaSand beads technology to create identifiable clusters of beads which can be distinguished in a conventional flow cytometer. The company provides products to detect influenzaA, influenzaB, influenza A H1N1, influenzaA H5N1, respiratory syncytial virus, human metapneumovirus, adenovirus, rhinovirus, bordetella pertussis, and chlamydophila pneumonia. It collaborates with pathology customers and IVD companies. GBL is headquartered in Melbourne, Victoria, Australia.

Genera Biosystems Ltd (GBI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genera Biosystems Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genera Biosystems Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Genera Biosystems Announces Private Placement of Shares for USD0.5 Million 10
Genera Biosystems Completes Private Placement Of Shares For US$0.12 Million 11
Genera Biosystems Announces Rights Issue Of Shares For US$1.1 Million 12
Debt Offering 13
Genera Biosystems Completes Private Placement of Notes for USD0.3 Million 13
Genera Biosystems Raises USD0.2 Million in Private Placement of Notes Due 2015 14
Genera Biosystems Completes Private Placement Of Notes Due 2015 For US$0.34 Million 15
Genera Biosystems Ltd – Key Competitors 16
Genera Biosystems Ltd – Key Employees 17
Genera Biosystems Ltd – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Oct 03, 2016: Genera Biosystems: 2016 Annual Report Highlights 19
Other Significant Developments 21
Nov 15, 2016: Genera Lodges 2016 Tax Return – To Receive $752k R&D Tax Rebate 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genera Biosystems Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genera Biosystems Ltd, Medical Devices Deals, 2011 to YTD 2017 8
Genera Biosystems Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genera Biosystems Announces Private Placement of Shares for USD0.5 Million 10
Genera Biosystems Completes Private Placement Of Shares For US$0.12 Million 11
Genera Biosystems Announces Rights Issue Of Shares For US$1.1 Million 12
Genera Biosystems Completes Private Placement of Notes for USD0.3 Million 13
Genera Biosystems Raises USD0.2 Million in Private Placement of Notes Due 2015 14
Genera Biosystems Completes Private Placement Of Notes Due 2015 For US$0.34 Million 15
Genera Biosystems Ltd, Key Competitors 16
Genera Biosystems Ltd, Key Employees 17

★海外企業調査レポート[Genera Biosystems Ltd (GBI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • DiaCarta Inc:医療機器:M&Aディール及び事業提携情報
    Summary DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection ki …
  • ALPCO Diagnostics:医療機器:M&Aディール及び事業提携情報
    Summary ALPCO Diagnostics (ALPCO) is a life science company that imports and distributes immunoassay based products. The company offers immunoassays, chemiluminescent assays, flow cytometry reagents, purified antibodies, recombinant proteins, and HPLC and MS-MS reagents. It provides food additives, …
  • SandRidge Energy, Inc.:企業の戦略・SWOT・財務分析
    SandRidge Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary SandRidge Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Serinus Energy plc (SEN):企業の財務・戦略的SWOT分析
    Summary Serinus Energy plc (Serinus), formerly Serinus Energy Inc, is an oil and gas company. It carries out exploration, development, and production of crude oil and natural gas assets in Romania and Tunisia. The company holds interest and operates Satu Mare Concession, an oil and gas exploration b …
  • National Institute on Drug Abuse-製薬・医療分野:企業M&A・提携分析
    Summary National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine …
  • Korea Research Institute of Bioscience and Biotechnology:製薬・医療:M&Aディール及び事業提携情報
    Summary Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute which provides bioinformatic services. The institute operates in the fields of strategic research, biomedical sciences, system biology and bioengineering, business development, and bioinfrastr …
  • Hokkaido Electric Power Co Inc (9509):企業の財務・戦略的SWOT分析
    Hokkaido Electric Power Co Inc (9509) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Sun Pharma Advanced Research Company Ltd (SPARC):企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • Celsius Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Celsius Therapeutics Inc (Celsius Therapeutics) is a biotechnology company that carries out single-cell genomic analysis to discover and develop precision medicines for autoimmune diseases and cancer. The company’s drug discovery is based on understanding specific cells that play a major rol …
  • Expro Holdings UK 3 Ltd:企業の戦略的SWOT分析
    Expro Holdings UK 3 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Canadian Solar Inc (CSIQ):電力:M&Aディール及び事業提携情報
    Summary Canadian Solar Inc (Canadian Solar) is a solar power company. It designs, develops, and manufactures solar ingots, wafers, modules, cells, and other solar power products. The company’s products include a range of solar modules for use in residential, commercial and industrial solar power gen …
  • Hopewell Holdings Ltd (54):企業の財務・戦略的SWOT分析
    Hopewell Holdings Ltd (54) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • KB Securities Vietnam Joint Stock Company:企業の戦略的SWOT分析
    KB Securities Vietnam Joint Stock Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Yanlord Land Group Ltd:企業の戦略・SWOT・財務情報
    Yanlord Land Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Yanlord Land Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • MallInckrodt Plc (MNK):医療機器:M&Aディール及び事業提携情報
    Summary Mallinckrodt Plc (Mallinckrodt) is develops, produces, commercializes, and distributes specialty pharmaceutical therapies and products. The company offers both branded and specialty generics for autoimmune and rare diseases in the specialty therapeutic areas of rheumatology, nephrology, neur …
  • Nova Scotia Power Inc:電力:M&Aディール及び事業提携情報
    Summary Nova Scotia Power Inc (NSP) a subsidiary of Emera Inc is a electric utility that provides electricity distribution services. The utility uses a fuel mix including hydro, tidal, wind, coal, oil, biomass and natural gas to generate electricity. It offers a range of home heating options, includ …
  • LPP SA (LPP):企業の財務・戦略的SWOT分析
    LPP SA (LPP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Kyowa Hakko Kirin Co., Ltd.:企業のM&A・事業提携・投資動向
    Kyowa Hakko Kirin Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kyowa Hakko Kirin Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Nuvia Ltd:企業の戦略的SWOT分析
    Nuvia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆